Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19 in Household Contacts

Inclusion Criteria:

• Men and women over 18 and under 65.
• Household contact with a confirmed case of COVID-19 by PCR for Sars-CoV-2.
• Initiate study medication within 4 days from the last close contact with the indexcase.
• The patient must not present symptoms suggestive of Covid19 (cough, dyspnea, fever> 37.5 C, fatigue, sore throat, myalgia, diarrhoea) at the time of admission to thestudy and from previous 14 days.
• Informed consent from the patient or legal representative.

Exclusion Criteria:

• History of infection confirmed by SARS-CoV-2.
• Positive IgG antibodies test for SARS-CoV-2 at the time of admission.
• Have received any dose of nitazoxanide within 7 days prior to screening.
• Known hypersensitivity to any of the study medication components.
• Use of any investigational or unregistered drug or vaccine within 30 days prior toscreening, or use planned during the study period.
• Inability to comply with study procedures.
• Current breastfeeding.
• Pregnancy.
• Intolerance or inability to take oral medication.
• History of severe liver disease (Child-Pugh B or C) and/or chronic kidney disease.